Pfizer reports Phase 2 data for 25‑valent pediatric pneumococcal vaccine
Pfizer presented results from a Phase 2 study of its investigational 25‑valent pneumococcal conjugate vaccine (PF‑07872412) in infants. The trial showed that the vaccine generated strong antibody responses to all 25 targeted serotypes and was tolerated similarly to the approved Prevnar 20. The candidate produced markedly higher antibody levels against serotype 3 – about 8.8‑fold after the third dose and roughly 15‑fold after the fourth – and the five new serotypes together represent roughly 30 % of pediatric invasive disease in the United States. Pfizer said the data support its ongoing Phase 3 program and its plan to launch a 35‑valent adult vaccine by the end of 2026.
Why it matters
The company indicated that, if Phase 3 confirms these findings, the vaccine could protect against about 84 % of invasive pneumococcal disease cases in U.S. children under five, expanding Pfizer’s pediatric vaccine portfolio. A successful launch would add a new revenue stream and could shift market share from existing pneumococcal products.
Key facts
- 1The vaccine targets serotypes that together cause approximately 84 % of invasive pneumococcal disease in U.S. children under five years old. finance.yahoo.com
- 2Antibody concentrations for serotype 3 were 8.8‑fold higher one month after the third dose and about 15‑fold higher one month after the fourth dose. finance.yahoo.com
- 3Serotype 3 accounts for 10.6 % of all invasive pneumococcal disease cases in U.S. children under five. finance.yahoo.com
- 4The five newly added serotypes are estimated to represent an additional ~30 % of pediatric invasive disease cases in the United States. finance.yahoo.com
- 5The Phase 2 study enrolled 401 infants and reported no serious adverse events. mugglehead.com
- 6Pfizer is running three Phase 3 pediatric studies that began in 2026 with up to 6,830 participants, and plans to start a 35‑valent adult vaccine program by the end of 2026. gurufocus.com
Summary written by AlphAI AI Desk from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.